|
Jun 17
|
Moderna (MRNA) Stock Declines While Market Improves: Some Information for Investors
|
|
Jun 17
|
Moderna Stock (NASDAQ:MRNA): Is There Life Beyond Disease Outbreaks?
|
|
Jun 16
|
Moderna Just Gave Investors Another Reason to Buy the Stock
|
|
Jun 15
|
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
|
|
Jun 14
|
Moderna (NASDAQ:MRNA) shareholders are still up 857% over 5 years despite pulling back 6.1% in the past week
|
|
Jun 14
|
Moderna’s Covid-19 vaccine meets primary efficacy endpoint in Phase III trial
|
|
Jun 13
|
Moderna says next-gen COVID shot effective in study
|
|
Jun 13
|
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
|
|
Jun 12
|
Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says
|
|
Jun 12
|
7 Struggling Stocks to Sell Before July 2024
|
|
Jun 12
|
Moderna announces positive Phase III data for Covid-19/Influenza mRNA vaccine
|
|
Jun 11
|
Moderna president: Company outlook 'stabilizing' thanks to new flu-COVID vaccine data
|
|
Jun 4
|
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
|
|
Jun 4
|
FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains
|
|
Jun 4
|
Company News for June 4, 2024
|
|
Jun 4
|
Moderna and MSD share encouraging three-year data from trial of melanoma therapy
|
|
Jun 3
|
Is Moderna Inc. (NASDAQ:MRNA) the Top Gene Therapy Stock to Invest in Now?
|
|
Jun 3
|
FDA considers updating COVID boosters, Novavax stock reacts
|
|
Jun 3
|
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
|
|
Jun 3
|
Update: RBC Raises Moderna's PT to $160 From $135 Amid RSV Vaccine Approval From US FDA, Keeps Outperform Rating
|